Search
forResearch 10 of 65
- BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i>-Mutant Thyroid Cancer
- Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
- Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
- Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Cutaneous toxicities of new treatments for melanoma
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Network pharmacology and molecular docking analysis on potential molecular targets and mechanism of action of BRAF inhibitors for application in wound healing
- Targeted therapy in melanoma
- Synthetic Approaches for Pharmacologically Active Decorated Six-Membered Diazines
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →